SNCA Share Price | Palisade Bio, Inc. Stock Analysis & Recommendation

Q: What does Palisade Bio, Inc. do?

Overview: Palisade Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for diseases of unmet medical need within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.Financial Snapshot: Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025) Market cap: USD 3.09 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.35 Return on Equity: -246.48% Price to Book: 0.58Contact Details: Address: 20271 Goldenrod Ln Ste 2024, GERMANTOWN MD: 20876 Tel: 1 301 3664841 Fax: 1 302 7301370 Website: https://senecabio.com/

Q: Is Palisade Bio, Inc. technically bullish or bearish?

As of 9 September 2025, the technical trend for Palisade Bio, Inc. has changed from mildly bearish to bearish. The current stance is bearish with weak strength, as indicated by the daily moving averages and the bearish signals from Dow Theory and Bollinger Bands. The weekly MACD shows a mildly bullish trend, but this is overshadowed by the overall bearish indicators. The stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -63.76% versus the S&P 500's 12.22%.

Results Declared: Palisade Bio, Inc. has declared results on 20 Mar 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

689.97 k

Shareholding (Dec 2025)

FII

6.07%

Held by 18 FIIs

DII

86.67%

Held by 17 DIIs

Promoter

3.46%

How big is Palisade Bio, Inc.?

22-Jun-2025

As of Jun 18, Palisade Bio, Inc. has a market capitalization of 3.09 million and reported net sales of 0.00 million with a net profit of -13.14 million over the last four quarters. Shareholder's funds are at 7.49 million and total assets at 10.88 million.

View full answer

What does Palisade Bio, Inc. do?

22-Jun-2025

Palisade Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for unmet medical needs. It has a market cap of $3.09 million and reported a net profit loss of $2 million as of March 2025.

View full answer

Who are in the management team of Palisade Bio, Inc.?

22-Jun-2025

As of March 2022, the management team of Palisade Bio, Inc. includes Dr. Kenneth Carter as Executive Chairman and Principal Executive Officer, with board members Dr. Mary Gray, Dr. David Mazzo, Dr. Cristina Csimma, Mr. Scott Ogilvie, and Mr. Sandford Smith, the latter three serving as independent directors.

View full answer

Is Palisade Bio, Inc. technically bullish or bearish?

20-Sep-2025

As of September 9, 2025, Palisade Bio, Inc. is in a bearish trend with weak strength, indicated by daily moving averages and bearish signals, despite a mildly bullish weekly MACD, and has underperformed the S&P 500 with a year-to-date return of -63.76%.

View full answer

Compare Palisade Bio, Inc. with Similar Stocks

Sonoma Pharmaceuticals, Inc.Synaptogenix, Inc.Tempest Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 297 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.56

Return on Equity

-364.57%

Price to Book

92.32

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-9 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

13.17%

6 Months

216.05%

1 Year

137.23%

2 Years

-65.26%

3 Years

-0.53%

4 Years

-99.71%

5 Years

-99.98%

Palisade Bio, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-0.20%

EBIT Growth (5y)

-8.62%

EBIT to Interest (avg)

-12.12

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.35

Sales to Capital Employed (avg)

0.02

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.32%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

92.32

EV to EBIT

-25.44

EV to EBITDA

-25.45

EV to Capital Employed

-161.59

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-364.57%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Mildly Bullish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 4 Schemes (3.8%)

Foreign Institutions

Held by 18 Foreign Institutions (6.07%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Sep 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -206.90% vs -3.57% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-10.00",
          "val2": "-2.90",
          "chgp": "-244.83%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.30",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-8.90",
          "val2": "-2.90",
          "chgp": "-206.90%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs -100.00% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -16.67% vs -17.07% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-18.10",
          "val2": "-14.90",
          "chgp": "-21.48%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.40",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-16.80",
          "val2": "-14.40",
          "chgp": "-16.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-10.00

-2.90

-244.83%

Interest

0.00

Exceptional Items

0.00

0.30

-100.00%

Consolidate Net Profit

-8.90

-2.90

-206.90%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is -206.90% vs -3.57% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-18.10

-14.90

-21.48%

Interest

0.00

Exceptional Items

0.40

0.00

Consolidate Net Profit

-16.80

-14.40

-16.67%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs -100.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -16.67% vs -17.07% in Dec 2024

All Annual Results

Company CV

About Palisade Bio, Inc.

Palisade Bio, Inc.

Pharmaceuticals & Biotechnology

Seneca Biopharma, Inc., formerly Neuralstem, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for diseases of unmet medical need. It is focused on finding and acquiring new assets, sciences and technologies that provide therapies for patients. It intends to focus on developing a pipeline of biopharmaceuticals and commercializing those products.

Company Coordinates

Company Details

20271 Goldenrod Ln Ste 2024 , GERMANTOWN MD : 20876

Tel: 1 301 3664841

https://senecabio.com/

Registrar Details